• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis expands inflammatory biomarker research via new partnership with Queen’s University Belfast
Share
News

ProAxsis expands inflammatory biomarker research via new partnership with Queen’s University Belfast

January 19, 2022
-
Posted by Jessica Robinson

ProAxsis Limited, the Belfast-based diagnostics company, today announces that in partnership with Dr Rich Williams, a Senior Lecturer in the School of Medicine, Dentistry and BioMedical Sciences at Queen’s University Belfast, it has been successful in its application to the Collaborative Studentship competition.

The collaborative project will involve recruitment of a PhD student to explore methods of early detection of inflammatory proteases, which is essential for treating life-debilitating inflammatory lung diseases, as well as many cancers, and identifying patients that require treatment earlier to improve quality of life.

The studentship is part-funded via the Northern Ireland Department for the Economy and Engineering and Physical Sciences Research Council (EPSRC), and as part of the collaboration, the student will spend a minimum of three months based at the ProAxsis laboratory.

Dr Timothy Ferguson, Head of Chemistry at ProAxsis, said: “Queen’s has an excellent track-record of collaborating with private industry to successfully deliver impactful, user-informed research so we are delighted to have been successful with this application and look forward to working with Dr Williams, his team and the new PhD student when they are appointed.”

Potential applicants for the role can find further details at:

Development and testing of a Proof of Concept Cathepsin S ProteaseTag Activity-Based Immunoassay

About ProAxsis

ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

The company has significantly expanded its product portfolio, via the recent in-licensing of a novel bone health assay from the University of Geneva, and a COVID-19 serology assay from AstraZeneca.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.

January 19, 2022

Related News

Other posts that you should not miss.
News

Aptamer Group and ProAxsis Limited enter partnership to improve global logistics and stability of diagnostic tests

August 19, 2021
-
Posted by David Ribeiro

York and Belfast, UK (August 19th, 2021) – Aptamer Group, the developer of custom affinity ligands to …

Read More
August 19, 2021
Posted by David Ribeiro
NEATstik®, News

ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

September 4, 2017
-
Posted by Webmaster

ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care …

Read More
September 4, 2017
Posted by Webmaster
News

ProAxsis announces commercial team expansion

June 21, 2021
-
Posted by David Ribeiro

As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce …

Read More
June 21, 2021
Posted by David Ribeiro
← PREVIOUS POST
ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
NEXT POST →
ProAxsis Ltd CEO Update Report – End Q4 2021
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • July 26, 2022
    ProAxsis announces additional key appointments
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis expands inflammatory biomarker research via new partnership with Queen’s University Belfast - ProAxsis